Name: Tamoxifen
SKU: 10540-29-1

Products Categories

Pharmaceutical (134)
Organic Chemicals (27)
Others (22)
Plant Extract (5)
Reagent (3)
Materials (3)

Basic Information

Molecular Structure:
CAS No.:	10540-29-1
Name:	Tamoxifen

Formula:	C₂₆H₂₉NO
Molecular Weight:	371.522
Synonyms:	Ethanamine,2-[4-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-;Ethanamine, 2-[4-[(1Z)-1,2-diphenyl-1-butenyl]phenoxy]-N,N-dimethyl-(9CI);Ethylamine, 2-[p-(1,2-diphenyl-1-butenyl)phenoxy]-N,N-dimethyl-, (Z)-(8CI);(Z)-2-[4-(1,2-Diphenyl-1-butenyl)phenoxy]-N,N-dimethylethanamine;ICI47699;Mammaton;Novaldex;Z-Tamoxifen;trans-Tamoxifen;? Tamoxifen;
EINECS:	234-118-0
Density:	1.042 g/cm³
Melting Point:	97-98 °C(lit.)
Boiling Point:	482.3 °C at 760 mmHg
Flash Point:	140 °C
Solubility:	Insoluble in water. Soluble in methanol, ethanol, propanol or propylene glycol.Soluble in dimethyl sulfoxide, dichloromethane and ethanol. Insoluble in water.
Appearance:	White crystalline solid
Hazard Symbols:	T, Xi
Risk Codes:	45-60-61-64-36/37/38
Safety:	53-45-36-26
PSA:	12.47000
LogP:	5.99610

Synthetic route

: 97818-83-2
(Z)-1-<4-(2-chloroethoxy)phenyl>-1,2-diphenyl-1-butene

: 124-40-3
dimethyl amine

: 10540-29-1
tamoxifen

Conditions

Conditions	Yield
In N,N-dimethyl-formamide at 65℃; for 12h; Inert atmosphere;	99%
In ethanol at 80℃; for 16h;	93%
In ethanol at 75℃; for 72h;	85 mg

: 108-01-0
2-(N,N-dimethylamino)ethanol

: (Z)-(1-(4-iodophenyl)but-1-ene-1,2-diyl)dibenzene

: 10540-29-1
tamoxifen

Conditions

Conditions	Yield
With copper(l) iodide; potassium carbonate at 110℃; for 53h; Inert atmosphere;	96%

: 69967-80-2
1-phenyl-1-(p-hydroxyphenyl)-2-phenylbut-1-ene

: 4584-46-7
(2-chloroethyl)dimethylamine hydrochloride

: 10540-29-1
tamoxifen

Conditions

Conditions	Yield
With potassium carbonate In ethanol; toluene at 80 - 85℃; for 3h; Inert atmosphere;	93%
With sodium ethanolate In ethanol for 24h; Heating;	60%
With sodium hydride 1.) DMF, 2.) 50 deg C; Yield given. Multistep reaction;

: 591-50-4
iodobenzene

: 1421712-14-2
(E)-N,N-dimethyl-2-(4-(1-phenyl-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)but-1-en-1-yl)phenoxy)ethanamine

: 10540-29-1
tamoxifen

Conditions

Conditions	Yield
With tri-tert-butyl phosphine; potassium hydroxide; bis(dibenzylideneacetone)-palladium(0) In tetrahydrofuran; water at 60℃; for 24h; Suzuki-Miyaura Coupling; regioselective reaction;	93%

: (Z)-N-((8-cyano-7-hydroxyquinolin-2-yl)methyl)-2-(4-(1,2-diphenylbut-1-en-1-yl)phenoxy)-N,N-dimethylethan-1-aminium methanesulfonate

A: 10540-29-1
tamoxifen

B: C11H7N2O2(1-)

Conditions

Conditions	Yield
In ethanol pH=7.2; UV-irradiation;	A 91% B n/a

: 604010-60-8
(Z)-2-(4-(1,2-diphenylbuta-1,3-dien-1-yl)phenoxy)-N,N-dimethylethanamine

: 10540-29-1
tamoxifen

Conditions

Conditions	Yield
With hydrogen; palladium on activated charcoal In ethyl acetate for 2h; atmospheric pressure;	85%
With hydrogen; palladium on activated charcoal

: 2-(4-(1,2-diphenylbuta-1,3-dien-1-yl)phenoxy)-N,N-dimethylethanamine

: 10540-29-1
tamoxifen

Conditions

Conditions	Yield
With palladium on activated charcoal; hydrogen In ethyl acetate at 22℃; for 2h;	85%

: 918793-63-2
(E)-1,2-diphenyl-1-butene boronic acid

: 93790-54-6
[2-(4-iodophenoxy)ethyl]dimethylamine

A: 16282-16-9
1,2-diphenyl-butan-1-one

B: 10540-29-1
tamoxifen

Conditions

Conditions	Yield
With sodium carbonate; tetrakis(triphenylphosphine) palladium(0) In 1,2-dimethoxyethane; water for 18h; Suzuki-Miyaura cross-coupling; Heating;	A n/a B 73%

...Expand

: 113619-15-1
(Z)-1-iodo-1,2-diphenyl-1-butene

: 194594-60-0
(4-(2-(dimethylamino)ethoxy)phenyl)boronic acid

: 10540-29-1
tamoxifen

Conditions

Conditions	Yield
With sodium carbonate; tetrakis(triphenylphosphine) palladium(0) In 1,2-dimethoxyethane; water Suzuki-Miyaura cross-coupling; Heating;	73%

: 1148025-82-4
(E)-1-(4-dimethylaminoethoxyphenyl)-1,2-diphenyl-2-(4-tolyl)thioethene

: 2386-64-3
ethylmagnesium chloride

: 10540-29-1
tamoxifen

Conditions

Conditions	Yield
With Ni(1,2-bis(diphenylphosphino)ethane)Cl2 In diethyl ether for 15h; Inert atmosphere; Reflux;	73%

Raw Materials

98-80-6

622-76-4

2170-06-1

104-87-0

100-66-3

540-38-5

591-50-4

93-54-9

Downstream Products

Total:142 Page 1 of 4 1 2 3 4 Next>>

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 10540-29-1

Consensus Reports

NTP 10th Report on Carcinogens. IARC Cancer Review: Group 1 IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man . 66 ,1996,p. 253.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) ; Human Sufficient Evidence IMEMDT IARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man . 66 ,1996,p. 253.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) (Benefits outweigh risk for breast cancer patients. 22 Feb, 1997). EPA Genetic Toxicology Program.

Specification

The Novadex is an organic compound with the formula C₂₆H₂₉NO. The IUPAC name of this chemical is 2-[4-[(Z)-1,2-diphenylbut-1-enyl]phenoxy]-N,N-dimethylethanamine. With the CAS registry number 10540-29-1, it is also named as 1-p-b-Dimethylaminoethoxyphenyl-trans-1,2-diphenylbut-1-ene. The product's categories are Active Pharmaceutical Ingredients; Protein Kinase Inhibitors and Activators; Intermediates & Fine Chemicals; Pharmaceuticals; Isotope Labeled Compounds. Besides, it is a white crystalline solid, which should be stored in a closed cool and dry place at temperature of 2 - 8 °C. It acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism. Also, it is a nonsteroidal estrogen antagonist of interest in the treatment of some forms of breast cancer and it is a Protein Kinase C inhibitor, and induces apoptosis in human malignant glioma cell lines.

Physical properties about Novadex are: (1)ACD/LogP: 7.88; (2)# of Rule of 5 Violations: 1; (3)ACD/LogD (pH 5.5): 5.04; (4)ACD/LogD (pH 7.4): 6.58; (5)ACD/BCF (pH 5.5): 827.41; (6)ACD/BCF (pH 7.4): 28455.67; (7)ACD/KOC (pH 5.5): 664.18; (8)ACD/KOC (pH 7.4): 22842.23; (9)#H bond acceptors: 2; (10)#Freely Rotating Bonds: 8; (11)Polar Surface Area: 12.47 Å²; (12)Index of Refraction: 1.582; (13)Molar Refractivity: 118.89 cm³; (14)Molar Volume: 356.2 cm³; (15)Polarizability: 47.13×10^-24cm³; (16)Surface Tension: 40.4 dyne/cm; (17)Density: 1.042 g/cm³; (18)Flash Point: 140 °C; (19)Enthalpy of Vaporization: 74.72 kJ/mol; (20)Boiling Point: 482.3 °C at 760 mmHg; (21)Vapour Pressure: 1.85E-09 mmHg at 25°C.

Preparation: this chemical can be prepared by (E,Z)-2-(4-bromophenyl)-1-{4-[2-(dimethylamino)ethoxy]phenyl}-1-phenyl-1-butene hydrochloride. This reaction will need reagent H₂, catalyst 5 percent Pd on C and solvent dimethylformamide. The reaction time is 60 min. The yield is about 92%.

When you are using this chemical, please be cautious about it as the following:
It may cause cancer and may impair fertility. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. Besides, this chemical is irritating to eyes, respiratory system and skin. It may cause harm to the unborn child and breast-fed babies. When you are using it, wear suitable protective clothing. In case of accident or if you feel unwell seek medical advice immediately (show the label where possible).

You can still convert the following datas into molecular structure:
(1)SMILES: O(c1ccc(cc1)/C(c2ccccc2)=C(\c3ccccc3)CC)CCN(C)C
(2)InChI: InChI=1/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-
(3)InChIKey: NKANXQFJJICGDU-QPLCGJKRBF
(4)Std. InChI: InChI=1S/C26H29NO/c1-4-25(21-11-7-5-8-12-21)26(22-13-9-6-10-14-22)23-15-17-24(18-16-23)28-20-19-27(2)3/h5-18H,4,19-20H2,1-3H3/b26-25-
(5)Std. InChIKey: NKANXQFJJICGDU-QPLCGJKRSA-N

The toxicity data is as follows:

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
mouse	LD50	intraperitoneal	575mg/kg (575mg/kg)		Journal of Antibiotics. Vol. 43, Pg. 1533, 1990.
mouse	LD50	oral	2150mg/kg (2150mg/kg)		Drugs of the Future. Vol. 9, Pg. 186, 1984.
rat	LD50	intraperitoneal	700mg/kg (700mg/kg)		Drugs of the Future. Vol. 9, Pg. 186, 1984.
rat	LD50	oral	4100mg/kg (4100mg/kg)		Drugs of the Future. Vol. 9, Pg. 186, 1984.
women	TDLo	oral	5600ug/kg/1W- (5.6mg/kg)	SKIN AND APPENDAGES (SKIN): BREAST: OTHER	British Medical Journal. Vol. 291, Pg. 1172, 1985.
women	TDLo	unreported	200ug/kg/D (0.2mg/kg)	GASTROINTESTINAL: NAUSEA OR VOMITING BLOOD: LEUKOPENIA BLOOD: THROMBOCYTOPENIA	Cancer Treatment Reports. Vol. 60, Pg. 1431, 1976.
women	TDLo	unreported	5600ug/kg/2W- (5.6mg/kg)	BLOOD: NORMOCYTIC ANEMIA MUSCULOSKELETAL: JOINTS	British Journal of Rheumatology. Vol. 33, Pg. 583, 1994.

10540-29-1

Refine

Country

Business Type

Certificate

Display

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

10540-29-1

Consensus Reports

Specification